Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) RatMine GViewer (Genome Viewer) Overgo Probe Designer ACP Haplotyper Genome Scanner
Aging & Age-Related Disease Cancer Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:crizotinib
go back to main search page
Accession:CHEBI:64310 term browser browse the term
Definition:A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Synonyms:exact_synonym: 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine
 related_synonym: (R)-crizotinib;   Formula=C21H22Cl2FN5O;   InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1;   InChIKey=KTEIFNKAUNYNJU-GFCCVEGCSA-N;   PF 2341066;   SMILES=C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl;   crizotinibum
 alt_id: CHEBI:77554
 xref: CAS:877399-52-5;   Drug_Central:4187;   KEGG:D09731;   LINCS:LSM-1027
 xref_mesh: MESH:C551994
 xref: PMID:21308771;   PMID:22129595;   PMID:22129984;   PMID:22191798;   PMID:22215748;   PMID:22233293;   PMID:22235099;   PMID:22277784;   PMID:22282074;   PMID:22311682;   PMID:22316363;   PMID:22321987;   PMID:22323827;   PMID:22385925;   PMID:22397764;   PMID:22435662;   PMID:22443113;   PMID:24427836;   PMID:24444403;   PMID:24455567;   PMID:24486291;   PMID:24491302;   PMID:24556908;   Reaxys:12133926;   Wikipedia:Crizotinib
 cyclic_relationship: is_enantiomer_of CHEBI:77555

show annotations for term's descendants           Sort by:
 
crizotinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP-binding cassette, sub-family B (MDR/TAP), member 1A multiple interactions
decreases activity		 ISO crizotinib inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin]; crizotinib inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; crizotinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]
crizotinib results in decreased activity of ABCB1 protein		 CTD PMID:22233293 PMID:28369651 NCBI chr 5:8,567,091...8,748,575
Ensembl chr 5:8,660,077...8,748,575 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 (Junior blood group) decreases activity ISO crizotinib results in decreased activity of ABCG2 protein CTD PMID:28369651 NCBI chr 6:58,584,491...58,692,451
Ensembl chr 6:58,584,523...58,695,676 		JBrowse link
G Abl1 c-abl oncogene 1, non-receptor tyrosine kinase decreases activity EXP crizotinib results in decreased activity of ABL1 protein CTD PMID:21812414 NCBI chr 2:31,688,244...31,807,093
Ensembl chr 2:31,688,376...31,804,227 		JBrowse link
G Acaca acetyl-Coenzyme A carboxylase alpha increases phosphorylation ISO crizotinib results in increased phosphorylation of ACACA protein CTD PMID:23707608 NCBI chr11:84,129,635...84,401,651
Ensembl chr11:84,129,672...84,401,651 		JBrowse link
G Akt1 thymoma viral proto-oncogene 1 decreases phosphorylation
multiple interactions		 ISO crizotinib results in decreased phosphorylation of AKT1 protein
EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]		 CTD PMID:22553343 PMID:22729845 NCBI chr12:112,653,821...112,674,884
Ensembl chr12:112,653,821...112,674,884 		JBrowse link
G Alk anaplastic lymphoma kinase decreases response to substance
affects response to substance
decreases activity
increases mutagenesis
decreases stability
decreases phosphorylation
multiple interactions		 ISO
EXP		 ALK gene mutant form results in decreased susceptibility to crizotinib; ALK gene SNP results in decreased susceptibility to crizotinib; ALK protein mutant form results in decreased susceptibility to crizotinib
ALK protein affects the susceptibility to crizotinib
crizotinib results in decreased activity of ALK protein mutant form
crizotinib results in increased mutagenesis of ALK gene mutant form; crizotinib results in increased mutagenesis of ALK protein mutant form
crizotinib results in decreased stability of ALK protein mutant form
crizotinib results in decreased phosphorylation of ALK protein; crizotinib results in decreased phosphorylation of ALK protein mutant form
crizotinib results in decreased activity of ALK protein; crizotinib results in decreased activity of ALK protein mutant form
[ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]] which results in decreased susceptibility to crizotinib; [crizotinib results in increased mutagenesis of ALK gene mutant form] which results in decreased susceptibility to crizotinib; [crizotinib results in increased mutagenesis of ALK protein mutant form] which results in decreased susceptibility to crizotinib; [crizotinib results in increased mutagenesis of ALK protein mutant form] which results in increased activity of ALK protein; [Ethylnitrosourea results in increased mutagenesis of ALK protein] inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein]; [Ethylnitrosourea results in increased mutagenesis of ALK protein] which results in decreased susceptibility to crizotinib; ALK gene SNP inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein mutant form]; ALK protein mutant form inhibits the reaction [crizotinib binds to and results in decreased activity of ALK protein]; ALK protein mutant form inhibits the reaction [crizotinib results in decreased activity of ALK protein]; ALK protein mutant form inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein]; crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK1 protein]; crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK3 protein]; crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN mRNA]; crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN protein]; crizotinib results in decreased phosphorylation of and results in decreased activity of ALK protein mutant form		 CTD PMID:20979473 PMID:21030459 PMID:21502504 PMID:21767331 PMID:21791641 PMID:21812414 PMID:21838707 PMID:21948233 PMID:22034911 PMID:22072639 PMID:22129595 PMID:22235099 PMID:22277784 PMID:22286764 PMID:22553343 PMID:22659414 PMID:22789543 PMID:22912387 PMID:23104988 PMID:29458018 NCBI chr17:71,868,988...72,604,702
Ensembl chr17:71,868,972...72,604,627 		JBrowse link
G Bcl2l11 BCL2-like 11 (apoptosis facilitator) increases expression
multiple interactions
affects response to substance		 ISO crizotinib results in increased expression of BCL2L11 protein
BCL2L11 protein affects the reaction [crizotinib results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [crizotinib results in increased expression of BCL2L11 protein]
BCL2L11 protein affects the susceptibility to crizotinib		 CTD PMID:22729845 NCBI chr 2:128,126,038...128,162,547
Ensembl chr 2:128,126,038...128,162,547 		JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 decreases expression
multiple interactions		 ISO crizotinib results in decreased expression of BIRC2 protein
MET gene mutant form promotes the reaction [crizotinib results in increased expression of BIRC2 protein]		 CTD PMID:22729845 NCBI chr 9:7,818,226...7,837,131
Ensembl chr 9:7,818,227...7,837,064 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression
multiple interactions		 ISO crizotinib results in decreased expression of BIRC5 protein
MET gene mutant form promotes the reaction [crizotinib results in increased expression of BIRC5 protein]		 CTD PMID:22729845 NCBI chr11:117,849,237...117,855,743
Ensembl chr11:117,849,251...117,855,743 		JBrowse link
G Cacna1c calcium channel, voltage-dependent, L type, alpha 1C subunit decreases activity ISO crizotinib results in decreased activity of CACNA1C protein CTD PMID:23707608 NCBI chr 6:118,587,240...119,197,384
Ensembl chr 6:118,587,240...119,196,890
Ensembl chr 6:118,587,240...119,196,890 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
increases activity		 ISO
EXP		 BCL2L11 protein affects the reaction [crizotinib results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [crizotinib results in increased cleavage of CASP3 protein]
[crizotinib co-treated with 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo(h)(1,6)naphthyridin-2(1H)-one] results in increased cleavage of CASP3 protein
crizotinib results in increased activity of CASP3 protein		 CTD PMID:22729845 PMID:22789543 PMID:23707608 NCBI chr 8:46,617,291...46,639,698
Ensembl chr 8:46,617,291...46,639,689 		JBrowse link
G Casp7 caspase 7 increases activity ISO crizotinib results in increased activity of CASP7 protein CTD PMID:23707608 NCBI chr19:56,396,833...56,442,348
Ensembl chr19:56,397,129...56,442,344 		JBrowse link
G Casp8 caspase 8 increases cleavage ISO Crizotinib results in increased cleavage of CASP8 protein CTD PMID:31706006 NCBI chr 1:58,795,233...58,847,503
Ensembl chr 1:58,795,374...58,847,503 		JBrowse link
G Cd44 CD44 antigen decreases expression ISO crizotinib results in decreased expression of CD44 mRNA; crizotinib results in decreased expression of CD44 protein CTD PMID:22973962 NCBI chr 2:102,811,141...102,901,669
Ensembl chr 2:102,811,141...102,901,665 		JBrowse link
G Cda cytidine deaminase decreases expression
multiple interactions		 ISO crizotinib results in decreased expression of CDA protein
[crizotinib results in decreased expression of CDA protein] which results in increased susceptibility to gemcitabine		 CTD PMID:22973962 NCBI chr 4:138,338,528...138,368,311
Ensembl chr 4:138,338,424...138,367,992 		JBrowse link
G Crkl v-crk avian sarcoma virus CT10 oncogene homolog-like multiple interactions ISO [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of CRKL protein CTD PMID:22683780 NCBI chr16:17,451,985...17,487,440
Ensembl chr16:17,451,987...17,487,434 		JBrowse link
G Egf epidermal growth factor multiple interactions
decreases response to substance		 ISO EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]; EGFR protein promotes the reaction [EGF protein results in decreased susceptibility to crizotinib]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in decreased susceptibility to crizotinib] CTD PMID:22553343 NCBI chr 3:129,677,574...129,755,322
Ensembl chr 3:129,677,565...129,755,316 		JBrowse link
G Egfr epidermal growth factor receptor decreases response to substance
multiple interactions		 ISO EGFR protein mutant form results in decreased susceptibility to crizotinib; EGFR protein results in decreased susceptibility to crizotinib
[EGFR protein results in increased phosphorylation of EGFR protein] which results in decreased susceptibility to crizotinib; EGFR protein promotes the reaction [EGF protein results in decreased susceptibility to crizotinib]; EGFR protein promotes the reaction [HBEGF protein results in decreased susceptibility to crizotinib]; EGFR protein promotes the reaction [TGFA protein results in decreased susceptibility to crizotinib]		 CTD PMID:21791641 PMID:22235099 PMID:22277784 PMID:22553343 NCBI chr11:16,752,203...16,913,907
Ensembl chr11:16,752,203...16,918,158 		JBrowse link
G Eml4 echinoderm microtubule associated protein like 4 decreases stability
multiple interactions
increases mutagenesis		 ISO crizotinib results in decreased stability of EML4 protein mutant form
[crizotinib results in increased mutagenesis of EML4 gene mutant form] which results in decreased susceptibility to crizotinib		 CTD PMID:21502504 PMID:22912387 NCBI chr17:83,350,930...83,480,361
Ensembl chr17:83,350,931...83,480,361 		JBrowse link
G Epcam epithelial cell adhesion molecule decreases expression ISO crizotinib results in decreased expression of EPCAM mRNA; crizotinib results in decreased expression of EPCAM protein CTD PMID:22973962 NCBI chr17:87,635,979...87,651,127
Ensembl chr17:87,635,979...87,651,129 		JBrowse link
G F3 coagulation factor III increases expression ISO crizotinib results in increased expression of F3 protein CTD PMID:25569083 NCBI chr 3:121,723,537...121,735,052
Ensembl chr 3:121,723,537...121,735,048 		JBrowse link
G Fads2 fatty acid desaturase 2 increases expression ISO crizotinib results in increased expression of FADS2 mRNA CTD PMID:23707608 NCBI chr19:10,062,765...10,101,503
Ensembl chr19:10,062,765...10,101,746 		JBrowse link
G Fasn fatty acid synthase increases expression ISO crizotinib results in increased expression of FASN mRNA CTD PMID:23707608 NCBI chr11:120,805,958...120,825,166
Ensembl chr11:120,805,846...120,824,547 		JBrowse link
G Fgfr1 fibroblast growth factor receptor 1 multiple interactions ISO [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] CTD PMID:22683780 NCBI chr 8:25,518,759...25,575,718
Ensembl chr 8:25,513,654...25,575,718 		JBrowse link
G Fshb follicle stimulating hormone beta decreases secretion ISO crizotinib results in decreased secretion of FSHB protein CTD PMID:22488744 NCBI chr 2:107,055,986...107,059,651
Ensembl chr 2:107,056,140...107,059,656 		JBrowse link
G Gpt glutamic pyruvic transaminase, soluble increases secretion ISO Crizotinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr15:76,696,726...76,699,675
Ensembl chr15:76,695,716...76,699,686 		JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions
decreases response to substance		 ISO EGFR protein promotes the reaction [HBEGF protein results in decreased susceptibility to crizotinib]; Erlotinib Hydrochloride inhibits the reaction [HBEGF protein results in decreased susceptibility to crizotinib]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein] CTD PMID:22553343 NCBI chr18:36,504,927...36,515,805
Ensembl chr18:36,504,927...36,515,805 		JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of CRKL protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK1 protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK3 protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of STAT3 protein; [crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein; [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] CTD PMID:22683780 NCBI chr 5:16,553,495...16,619,439
Ensembl chr 5:16,553,495...16,620,152 		JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-Coenzyme A reductase increases expression ISO crizotinib results in increased expression of HMGCR mRNA CTD PMID:23707608 NCBI chr13:96,648,962...96,670,936
Ensembl chr13:96,648,967...96,670,936 		JBrowse link
G Hmgcs1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 increases expression ISO crizotinib results in increased expression of HMGCS1 mRNA CTD PMID:23707608 NCBI chr13:119,690,351...119,708,260
Ensembl chr13:119,690,379...119,708,260 		JBrowse link
G Insig1 insulin induced gene 1 increases expression ISO crizotinib results in increased expression of INSIG1 mRNA CTD PMID:23707608 NCBI chr 5:28,071,412...28,078,662
Ensembl chr 5:28,071,363...28,078,662 		JBrowse link
G Kcnh2 potassium voltage-gated channel, subfamily H (eag-related), member 2 decreases activity ISO crizotinib results in decreased activity of KCNH2 protein CTD PMID:23707608 NCBI chr 5:24,319,589...24,351,684
Ensembl chr 5:24,319,589...24,351,604 		JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase decreases response to substance ISO KIT gene mutant form results in decreased susceptibility to crizotinib CTD PMID:22277784 NCBI chr 5:75,574,987...75,656,722
Ensembl chr 5:75,574,916...75,656,722 		JBrowse link
G Kras Kirsten rat sarcoma viral oncogene homolog decreases response to substance ISO KRAS protein mutant form results in decreased susceptibility to crizotinib CTD PMID:22235099 NCBI chr 6:145,216,699...145,250,420
Ensembl chr 6:145,216,699...145,250,239 		JBrowse link
G Lck lymphocyte protein tyrosine kinase decreases activity ISO crizotinib results in decreased activity of LCK protein CTD PMID:21812414 NCBI chr 4:129,548,344...129,573,641
Ensembl chr 4:129,548,344...129,573,641 		JBrowse link
G Lhb luteinizing hormone beta decreases secretion ISO crizotinib results in decreased secretion of LHB protein CTD PMID:22488744 NCBI chr 7:45,417,608...45,421,855
Ensembl chr 7:45,420,820...45,421,897
Ensembl chr 7:45,420,820...45,421,897 		JBrowse link
G Mapk1 mitogen-activated protein kinase 1 multiple interactions
decreases phosphorylation		 ISO [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK1 protein; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK1 protein]; EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein] CTD PMID:21266357 PMID:21502504 PMID:22034911 PMID:22553343 PMID:22683780 PMID:22729845 PMID:23104988 NCBI chr16:16,983,382...17,047,453
Ensembl chr16:16,983,382...17,047,453 		JBrowse link
G Mapk3 mitogen-activated protein kinase 3 multiple interactions
decreases phosphorylation		 ISO [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK3 protein; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK3 protein]; EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein] CTD PMID:21266357 PMID:21502504 PMID:22034911 PMID:22553343 PMID:22683780 PMID:22729845 PMID:23104988 NCBI chr 7:126,759,626...126,765,816
Ensembl chr 7:126,759,601...126,765,819 		JBrowse link
G Met met proto-oncogene decreases activity
affects response to substance
increases response to substance
increases mutagenesis
multiple interactions
decreases phosphorylation		 ISO crizotinib results in decreased activity of MET protein
MET protein affects the susceptibility to Crizotinib
MET gene mutant form results in increased susceptibility to crizotinib
crizotinib results in increased mutagenesis of MET protein
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to crizotinib; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of CRKL protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK1 protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK3 protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of STAT3 protein; [crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; [crizotinib results in increased mutagenesis of MET protein] inhibits the reaction [crizotinib binds to and results in decreased activity of MET protein]; [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]; crizotinib binds to and results in decreased activity of MET protein; crizotinib inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of MET protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of STAT3 protein]; MET gene mutant form promotes the reaction [crizotinib results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [crizotinib results in increased expression of BCL2L11 protein]; MET gene mutant form promotes the reaction [crizotinib results in increased expression of BIRC2 protein]; MET gene mutant form promotes the reaction [crizotinib results in increased expression of BIRC5 protein]; MET gene mutant form promotes the reaction [crizotinib results in increased expression of XIAP protein]
Crizotinib results in decreased phosphorylation of MET protein		 CTD PMID:21266357 PMID:21405128 PMID:21812414 PMID:22233293 PMID:22683780 PMID:22729845 PMID:22948846 PMID:31639374 PMID:31706006 NCBI chr 6:17,463,349...17,573,980
Ensembl chr 6:17,463,800...17,573,980 		JBrowse link
G Mst1r macrophage stimulating 1 receptor (c-met-related tyrosine kinase) decreases activity EXP crizotinib results in decreased activity of MST1R protein CTD PMID:21812414 NCBI chr 9:107,906,858...107,920,383
Ensembl chr 9:107,906,873...107,920,383 		JBrowse link
G Mycn v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived multiple interactions ISO crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN mRNA]; crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN protein] CTD PMID:22286764 NCBI chr12:12,936,093...12,941,836
Ensembl chr12:12,936,093...12,941,914 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase family, member 1 increases cleavage
multiple interactions		 ISO Crizotinib results in increased cleavage of PARP1 protein
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Crizotinib results in increased cleavage of PARP1 protein]		 CTD PMID:31639374 PMID:31706006 NCBI chr 1:180,568,891...180,600,999
Ensembl chr 1:180,568,924...180,601,254 		JBrowse link
G Prom1 prominin 1 decreases expression ISO crizotinib results in decreased expression of PROM1 mRNA; crizotinib results in decreased expression of PROM1 protein CTD PMID:22973962 NCBI chr 5:43,993,621...44,102,047
Ensembl chr 5:43,993,620...44,102,032 		JBrowse link
G Ros1 Ros1 proto-oncogene decreases phosphorylation ISO crizotinib results in decreased phosphorylation of ROS protein mutant form CTD PMID:22617245 NCBI chr10:52,044,863...52,195,398
Ensembl chr10:52,045,721...52,195,244 		JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation ISO crizotinib results in decreased phosphorylation of RPS6 protein CTD PMID:22034911 NCBI chr 4:86,854,099...86,857,367
Ensembl chr 4:86,854,660...86,857,412 		JBrowse link
G Scn5a sodium channel, voltage-gated, type V, alpha decreases activity ISO crizotinib results in decreased activity of SCN5A protein CTD PMID:23707608 NCBI chr 9:119,483,404...119,579,030
Ensembl chr 9:119,483,408...119,579,016 		JBrowse link
G Srebf2 sterol regulatory element binding factor 2 increases expression ISO crizotinib results in increased expression of SREBF2 mRNA CTD PMID:23707608 NCBI chr15:82,147,269...82,205,379
Ensembl chr15:82,147,181...82,205,379 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 decreases phosphorylation
multiple interactions		 ISO crizotinib results in decreased phosphorylation of STAT3 protein
[[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of STAT3 protein; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of STAT3 protein]		 CTD PMID:22034911 PMID:22553343 PMID:22683780 PMID:22729845 NCBI chr11:100,886,806...100,939,594
Ensembl chr11:100,885,098...100,939,540 		JBrowse link
G Tek TEK receptor tyrosine kinase decreases activity EXP crizotinib results in decreased activity of TEK protein CTD PMID:21812414 NCBI chr 4:94,739,086...94,874,976
Ensembl chr 4:94,739,289...94,874,976 		JBrowse link
G Tgfa transforming growth factor alpha multiple interactions
decreases response to substance		 ISO EGFR protein promotes the reaction [TGFA protein results in decreased susceptibility to crizotinib]; Erlotinib Hydrochloride inhibits the reaction [TGFA protein results in decreased susceptibility to crizotinib]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein] CTD PMID:22553343 NCBI chr 6:86,195,038...86,275,744
Ensembl chr 6:86,195,223...86,275,719 		JBrowse link
G Twist1 twist basic helix-loop-helix transcription factor 1 decreases response to substance ISO TWIST1 protein results in decreased susceptibility to crizotinib CTD PMID:22155737 NCBI chr12:33,957,671...33,959,831
Ensembl chr12:33,957,671...33,959,829 		JBrowse link
G Vim vimentin decreases expression ISO crizotinib results in decreased expression of VIM protein CTD PMID:22973962 NCBI chr 2:13,574,311...13,582,826
Ensembl chr 2:13,573,927...13,582,826 		JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression
multiple interactions		 ISO crizotinib results in decreased expression of XIAP protein
MET gene mutant form promotes the reaction [crizotinib results in increased expression of XIAP protein]		 CTD PMID:22729845 NCBI chr  X:42,059,613...42,109,664
Ensembl chr  X:42,059,679...42,109,656 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 21569
    role 21548
      application 21029
        indicator 8747
          biomarker 6521
            crizotinib 53
              rac-crizotinib 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 21569
    subatomic particle 21555
      composite particle 21555
        hadron 21555
          baryon 21555
            nucleon 21555
              atomic nucleus 21555
                atom 21555
                  main group element atom 21461
                    p-block element atom 21461
                      carbon group element atom 21254
                        carbon atom 21151
                          organic molecular entity 21151
                            organic molecule 21045
                              organic cyclic compound 20601
                                organic heterocyclic compound 19451
                                  heteroarene 16959
                                    monocyclic heteroarene 13506
                                      azole 12764
                                        diazole 8365
                                          pyrazoles 1588
                                            pyrazolylpiperidine 53
                                              3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine 53
                                                crizotinib 53
                                                  rac-crizotinib 0
paths to the root